Exzell Pharma is a pharmaceutical company that has been serving the Canadian market since 2014 and recently became a subsidiary of Biolab Pharma Inc.
With a mission to bring innovative products from around the world to the Canadian market, Exzell Pharma aims to provide new and effective therapeutic options to patients in areas of unmet need.
After being incorporated into Biolab in 2022, the possibilities and motivation for Exzell Pharma have increased even more to become a leading source of safe, effective and affordable healthcare products in Canada.
In the pursuit of excellence and commitment to developing health solutions and promoting well-being, in 2023 the division dedicated to the pets, Exzell Animal Health is proof of our passion for improving the quality of life not only of people but also of their pets.
The acquisition of Exzell Pharma represents a major growth opportunity for both the Brazilian and Canadian markets, through the expansion of the product portfolio. The purchase of Exzell Pharma also offers a significant growth opportunity for the Biolab group, by establishing an international export platform from Canada.
